EGFR and non-small cell lung carcinoma: Osimertinib is associated with cardiotoxicity, including severe QT interval prolongation, which necessitates detailed evaluation due to its increasing use.<h4>Methods</h4>This retrospective, single-center study conducted at Jilin University China-Japan Union Hospital evaluated electrocardiographic changes with EGFR-mutated NSCLC treated with osimertinib.